Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | family S10 non peptidase ue (S10 family) | 0.0557 | 0.3328 | 0.8732 |
Brugia malayi | Sodium:neurotransmitter symporter family protein | 0.0166 | 0.0237 | 0.0621 |
Echinococcus multilocularis | lysosomal protective protein | 0.0618 | 0.3811 | 1 |
Echinococcus granulosus | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0605 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Schistosoma mansoni | beta-catenin | 0.0204 | 0.0535 | 0.1403 |
Echinococcus granulosus | lysosomal protective protein | 0.0618 | 0.3811 | 0.9735 |
Echinococcus multilocularis | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0621 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S10, putative | 0.0618 | 0.3811 | 0.5 |
Echinococcus granulosus | beta catenin | 0.0204 | 0.0535 | 0.1365 |
Trypanosoma cruzi | serine peptidase, Clan SC, Family S10, putative | 0.0618 | 0.3811 | 0.5 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0166 | 0.0237 | 0.0621 |
Loa Loa (eye worm) | Sodium:neurotransmitter symporter family protein | 0.0166 | 0.0237 | 0.0621 |
Onchocerca volvulus | Uncharacterized serine carboxypeptidase homolog | 0.0618 | 0.3811 | 1 |
Echinococcus granulosus | hypothetical protein | 0.0632 | 0.3915 | 1 |
Trypanosoma brucei | serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Mycobacterium tuberculosis | Probable glutamate racemase MurI | 0.1401 | 1 | 0.5 |
Trypanosoma cruzi | serine carboxypeptidase (CBP1), putative | 0.0618 | 0.3811 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0618 | 0.3811 | 1 |
Brugia malayi | Serine carboxypeptidase F41C3.5 precursor | 0.0618 | 0.3811 | 1 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0166 | 0.0237 | 0.0621 |
Leishmania major | serine carboxypeptidase (CBP1), putative,serine peptidase, Clan SC, Family S10 | 0.0618 | 0.3811 | 0.5 |
Schistosoma mansoni | family S10 unassigned peptidase (S10 family) | 0.0618 | 0.3811 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0166 | 0.0237 | 0.0621 |
Echinococcus granulosus | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0605 |
Trypanosoma cruzi | serine carboxypeptidase (CBP1), putative | 0.0618 | 0.3811 | 0.5 |
Echinococcus multilocularis | beta catenin | 0.0204 | 0.0535 | 0.1403 |
Schistosoma mansoni | family S10 non-peptidase homologue (S10 family) | 0.0618 | 0.3811 | 1 |
Echinococcus multilocularis | sodium and chloride dependent glycine | 0.0166 | 0.0237 | 0.0621 |
Treponema pallidum | glutamate racemase | 0.1401 | 1 | 0.5 |
Echinococcus granulosus | family S10 non peptidase ue S10 family | 0.0557 | 0.3328 | 0.8501 |
Schistosoma mansoni | hypothetical protein | 0.0496 | 0.2847 | 0.747 |
Brugia malayi | Armadillo/beta-catenin-like repeat family protein | 0.0204 | 0.0535 | 0.1403 |
Mycobacterium ulcerans | glutamate racemase | 0.1401 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0166 | 0.0237 | 0.0621 |
Loa Loa (eye worm) | HMP-2 protein | 0.0204 | 0.0535 | 0.1403 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Activity (ADMET) | = 89 % | Cytotoxicity against human FRT-Jurkat cells assessed as reduction of cell viability by measuring cleaved caspase 3 at 10 uM by flow cytometer | ChEMBL. | No reference |
Inhibition (binding) | = 17 % | Inhibition of NFkappaB in human FRT-Jurkat cells expressing GFP assessed as reduction of TNF expression at 10 uM after 24 hrs by flow cytometry relative to control | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.